The biology of breast carcinoma

The biology of breast carcinoma is complex, with multiple factors contributing to its development and progression. The current review focuses on the role of several critical genes including estrogen receptor, progesterone receptor, retinoic acid receptor‐β, epidermal growth factor receptor family members, p53, BRCA1, and BRCA2 as risk factors for the development of disease, predictors of prognosis and response to therapy, and as therapeutic targets. Studies of the biology of these and other genes that contribute to the development and progression of breast carcinoma have had and will continue to have great impact on all aspects of disease management. Cancer 2003;97(3 Suppl):825–33. © 2003 American Cancer Society.

[1]  R. Sutherland,et al.  Cyclins and breast cancer , 2005, Journal of Mammary Gland Biology and Neoplasia.

[2]  S. Tretli,et al.  Pre-morbid body-mass-index in breast cancer: Reversed effect on survival in hormone receptor negative patients , 2005, Breast Cancer Research and Treatment.

[3]  L. E. Faber,et al.  Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells , 2001, Breast Cancer Research and Treatment.

[4]  T. Kute,et al.  DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines* , 2001, Breast Cancer Research and Treatment.

[5]  M. Widschwendter,et al.  Epigenetic Downregulation of the Retinoic Acid Receptor-β2 Gene in Breast Cancer , 2001, Journal of Mammary Gland Biology and Neoplasia.

[6]  P. Hall,et al.  Prognostic and predictive factors. , 2004, Methods in molecular medicine.

[7]  J. Shimazaki,et al.  Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer , 2004, Breast Cancer Research and Treatment.

[8]  Qifeng Yang,et al.  Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas. , 2002, Anticancer research.

[9]  P. Chappuis,et al.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.

[10]  R. Pili,et al.  Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. , 2002, Cancer research.

[11]  Takao Matsuda,et al.  Contribution of Estrogen Receptor α to Oncogenic K-Ras-mediated NIH3T3 Cell Transformation and Its Implication for Escape from Senescence by Modulating the p53 Pathway* , 2002, The Journal of Biological Chemistry.

[12]  B. Gusterson,et al.  Concomitant inactivation of p53 and Chk2 in breast cancer , 2002, Oncogene.

[13]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[15]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  丸山 聡.  Suppression by estrogen receptor β of AP-1 mediated transactivation through estrogen receptor α , 2002 .

[17]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[18]  Y. Kakeji,et al.  Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. , 2002, Surgery.

[19]  M. Wolff,et al.  Waf-1 (p21) and p53 polymorphisms in breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  R. Nicholson,et al.  Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. , 2002, Cancer research.

[21]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[22]  A. Bird.  Methylation Talk Between Histones and DNA , 2001, Science.

[23]  R. Coombes,et al.  Estrogen receptors and proliferation markers in primary and recurrent breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Wen-Hwa Lee,et al.  BRCA1 and BRCA2 in breast cancer , 2001, The Lancet.

[25]  Jian-ming Zheng,et al.  Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression☆ ☆ This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project. , 2001, Steroids.

[26]  M. Dowsett,et al.  HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. , 2001, Cancer research.

[27]  C. Deng,et al.  Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice , 2001, Oncogene.

[28]  Y. Bignon,et al.  Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway , 2001, Oncogene.

[29]  N. Rosen,et al.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.

[30]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[31]  E. Liu,et al.  BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents , 2001, Oncogene.

[32]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[33]  Qifeng Yang,et al.  Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas , 2001, Cancer.

[34]  R. Momparler,et al.  Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells , 2001, Cancer Chemotherapy and Pharmacology.

[35]  J. Varley,et al.  The relationship between radiation-induced G1arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations , 2001, British Journal of Cancer.

[36]  M. King,et al.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.

[37]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[38]  J. Gustafsson,et al.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. , 2001, Cancer research.

[39]  Takashi Suzuki,et al.  Progesterone Receptor A and B Isoforms in the Human Breast and Its Disorders , 2001, Japanese journal of cancer research : Gann.

[40]  Qifeng Yang,et al.  Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. , 2001, The American journal of pathology.

[41]  T. Löning,et al.  Progesterone Receptor Isoforms, PR-B and PR-A, in Breast Cancer: Correlations with Clinicopathologic Tumor Parameters and Expression of AP-1 Factors , 2001, Hormone Research in Paediatrics.

[42]  Y. Miyoshi,et al.  Quantitative analysis of estrogen receptor‐β mRNA and its variants in human breast cancers , 2000, International journal of cancer.

[43]  J. Sparano,et al.  Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. , 2000, Frontiers in bioscience : a journal and virtual library.

[44]  J. Boyle,et al.  Chromosome instability in fibroblasts derived from Li–Fraumeni syndrome families without TP53 mutations , 2000, British Journal of Cancer.

[45]  C. Benz,et al.  Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  G. Mor,et al.  Absence of Estrogen Receptor‐β Expression in Metastatic Ovarian Cancer , 2000 .

[47]  Y. Kuppumbatti,et al.  Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells , 2000, Oncogene.

[48]  M. Mayo,et al.  Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. , 2000, Journal of the National Cancer Institute.

[49]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[50]  C. Allis,et al.  Acetylation and chromosomal functions. , 2000, Current opinion in cell biology.

[51]  John M. Daly,et al.  ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.

[52]  G. Liu,et al.  Estrogen receptor protects p53 from deactivation by human double minute-2. , 2000, Cancer research.

[53]  國末 浩範.  Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2 , 2000 .

[54]  S. Sukumar,et al.  Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells , 2000, Oncogene.

[55]  Jorma Isola,et al.  Estrogen Receptor β Is Coexpressed with ERα and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer , 2000 .

[56]  A. Buzdar.  Hormonal aspects of breast cancer: Introduction , 2000 .

[57]  R. Lotan,et al.  Differential expression of nuclear retinoid receptors in normal and malignant prostates. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Bird,et al.  Methylation-Induced Repression— Belts, Braces, and Chromatin , 1999, Cell.

[59]  S. Lippman,et al.  Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis. , 1999, The American journal of pathology.

[60]  L. Moore,et al.  Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. , 1999, Cancer research.

[61]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.

[63]  N. Sadick,et al.  Estrogen and progesterone receptors: their role in postsclerotherapy angiogenesis telangiectatic matting (TM). , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[64]  M. Somerfield,et al.  American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[66]  Helmut Dotzlaw,et al.  Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. , 1999, Cancer research.

[67]  M. Kerin,et al.  Coexpression of Estrogen Receptor α and β: Poor Prognostic Factors in Human Breast Cancer? , 1999 .

[68]  V. Seewaldt,et al.  Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[69]  R. White,et al.  BRCA1 is associated with the centrosome during mitosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Rice,et al.  Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells , 1998, Oncogene.

[71]  A. Miller,et al.  Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. , 1998, Journal of the National Cancer Institute.

[72]  A. Ferguson,et al.  Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression , 1998, Oncogene.

[73]  E. Diamandis,et al.  Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[75]  A. Sabichi,et al.  Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. , 1998, Journal of the National Cancer Institute.

[76]  G. Sourvinos,et al.  Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. , 1998, Biochemical and biophysical research communications.

[77]  D. Haber,et al.  Hereditary breast cancer. , 1998, Annual review of medicine.

[78]  J. Gustafsson,et al.  Differential Response of Estrogen Receptor a and Estrogen Receptor b to Partial Estrogen Agonists/Antagonists , 1998 .

[79]  S. Baylin,et al.  Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells* , 1997, The Journal of Biological Chemistry.

[80]  S. Cheng,et al.  The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. , 1997, Biochemical and biophysical research communications.

[81]  V. Moudgil,et al.  Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells , 1997, Oncogene.

[82]  R. Sutherland,et al.  Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.

[83]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[84]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[85]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[86]  D. Evans,et al.  Li-Fraumeni syndrome--a molecular and clinical review. , 1997, British Journal of Cancer.

[87]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[88]  T. Arakawa,et al.  ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. , 1996, Biochemical and biophysical research communications.

[89]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[90]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[91]  J. S. Foster,et al.  Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. , 1996, Molecular endocrinology.

[92]  S. Weitzman,et al.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  John Calvin Reed,et al.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells , 1996, Molecular and cellular biology.

[94]  S. Kamel,et al.  Identification of a chemoprevention cohort from a population of women at high risk for breast cancer , 1996, Journal of cellular biochemistry. Supplement.

[95]  S. Masushige,et al.  A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression. , 1996, The Biochemical journal.

[96]  R. Dickson,et al.  Mammary Tumor Cell Cycle, Differentiation, and Metastasis , 1996, Cancer Treatment and Research.

[97]  J. Graham,et al.  Preferential Stimulation of Human Progesterone Receptor B Expression by Estrogen in T-47D Human Breast Cancer Cells (*) , 1995, The Journal of Biological Chemistry.

[98]  S. Jhanwar,et al.  Hormonal Regulation of the p53 Tumor Suppressor Protein in T47D Human Breast Carcinoma Cell Line (*) , 1995, The Journal of Biological Chemistry.

[99]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[100]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[101]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[102]  M. Pfahl,et al.  A specific defect in the retinoic acid response associated with human lung cancer cell lines. , 1994, Cancer research.

[103]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[104]  R. Lotan,et al.  Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. , 1994, Cancer research.

[105]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[106]  H. Tsou,et al.  Down-Regulation of Retinoic Acid Receptor 3 in Mammary Carcinoma Cell Lines and Its Up-Regulation in Senescing Normal Mammary Epithelial Cells 1 , 2005 .

[107]  G. Viale,et al.  p53 Immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix , 1993, The Journal of pathology.

[108]  B. Houle,et al.  Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[109]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[110]  R. Clarke,et al.  Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. , 1992, Critical reviews in oncology/hematology.

[111]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.

[112]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[113]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[114]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[115]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[116]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[117]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[118]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[119]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[120]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[121]  C. Osborne,et al.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. , 1983, Cancer research.

[122]  B. Macmahon,et al.  Menopause and breast cancer risk. , 1972, Journal of the National Cancer Institute.